Antibodies having pan-antiviral activity and methods thereof

Patent metadata

Field	Value
Publication number	US-2025051425-A1
Application number	US-202218719735-A
Country	US
Kind code	A1
Filing date	Dec 14, 2022
Priority date	Dec 14, 2021
Publication date	Feb 13, 2025
Grant date	—

Abstract

Described herein are antibodies having pan-antiviral activity. In certain embodiments, the antibodies recognize glycosylation patterns specific to viral proteins, but not found on host proteins. Also described herein are methods of preventing, treating, and/or ameliorating viral infections using the antibodies of the disclosure.

First claim

1 . An isolated antigen-binding protein comprising a light chain polypeptide and a heavy chain polypeptide, wherein
the light chain polypeptide comprises:
a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and
the heavy chain polypeptide comprises:
a CDR 1 comprising the amino acid sequence of SEQ ID NO: 4;
a CDR2 comprising the amino acid sequence of SEQ ID NO: 5; and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

2 . The antigen-binding protein of claim 1 , wherein the light chain polypeptide comprises the amino acid sequence of SEQ ID NO: 7, and wherein the heavy chain polypeptide comprises the amino acid sequence of SEQ ID NO: 8.

3 . The antigen-binding protein of claim 1 , wherein the antigen-binding protein comprises at least one selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a variable fragment (Fv), an antigen-binding fragment (Fab or F(ab) 2 ), a single chain antibody (scFv), a camelid antibody and a humanized antibody.

4 . The antigen-binding protein of claim 1 , wherein the antigen-binding protein binds to viral proteins of two or more viruses from different viral families.

5 . The antigen-binding protein of claim 4 , wherein the antigen-binding protein binds to a viral protein from a Orthomyxoviridae family virus and a viral protein from a Coronaviridae family virus.

6 . The antigen-binding protein of claim 4 , wherein the antigen-binding protein binds to a viral protein from an influenza virus and a viral protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 . The antigen-binding protein of claim 1 , wherein the antigen-binding protein binds to a glycosylation feature specific to a viral protein which is not found in a protein of a host of the virus.

8 . The antigen-binding protein of claim 7 , wherein the glycosylation feature comprises an N-acetylglucosamine (GlcNAc) residue on a non-reducing end of an oligosaccharide.

9 . A composition comprising the antigen-binding protein of claim 1 and at least one pharmaceutically acceptable carrier.

10 . The composition of claim 9 , further comprising:
a compound for treating, preventing, or ameliorating an infection by an influenza virus in a subject; or a compound for treating, preventing, or ameliorating an infection by SARS-CoV-2 virus in a subject.

11 . A nucleic acid encoding the antigen-binding protein of claim 1 .

12 . The nucleic acid of claim 11 , wherein the nucleic acid comprises a first segment comprising the nucleotide sequence of SEQ ID NO: 9, and a second segment comprising the nucleotide sequence of SEQ ID NO: 10.

13 . A method of preventing, treating, or ameliorating an infection by a virus in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody of claim 1 .

14 . The method of claim 13 , wherein a protein of the virus has a glycosylation feature is not found in a protein of a host of the virus, and wherein the antibody specifically recognizes the glycosylation feature.

15 . The method of claim 14 , wherein the glycosylation feature comprises an N-acetylglucosamine (GlcNAc) residue on a non-reducing end of an oligosaccharide.

16 . The method of claim 13 , wherein the virus is an Orthomyxoviridae family virus or a Coronaviridae family virus.

17 . The method of claim 13 , wherein the virus is an influenza virus or SARS-CoV-2 virus.

18 . The method of claim 17 , wherein the subject is further administered a second compound suitable for treating, preventing and/or ameliorating an influenza virus infection, or a second compound suitable for treating, preventing, and/or ameliorating COVID-19.

19 . The method of claim 13 , wherein the subject is a mammal.

20 . The method of claim 13 , wherein the subject is a human.

Assignees

• Univ Yale

Inventors

• Iwasaki Akiko
• Yang Yexin

Classifications

• C07K16/112

  Retroviridae (F), e.g. leukemia viruses · CPC title

• C07K16/104

  Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2] · CPC title

• C07K16/108

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title